Home Cart Sign in  
Chemical Structure| 554-57-4 Chemical Structure| 554-57-4

Structure of Methazolamide
CAS No.: 554-57-4

Chemical Structure| 554-57-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Methazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively.

Synonyms: L584601; CL 8490; N Methylacetazolamide

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Methazolamide

CAS No. :554-57-4
Formula : C5H8N4O3S2
M.W : 236.27
SMILES Code : CC(/N=C1SC(S(N)(=O)=O)=NN/1C)=O
Synonyms :
L584601; CL 8490; N Methylacetazolamide
MDL No. :MFCD00083416
InChI Key :FLOSMHQXBMRNHR-UHFFFAOYSA-N
Pubchem ID :4100

Safety of Methazolamide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H332
Precautionary Statements:P280

Isoform Comparison

Biological Activity

Target
  • Carbonic Anhydrase IV

    bCAIV, Ki:36 nM

  • Carbonic Anhydrase I

    hCAI, Ki:50 nM

  • Carbonic Anhydrase II

    hCAII, Ki:14 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03165045 - Active, not recruiting January 31, 2019 -
NCT03362021 - Recruiting March 2019 Greece ... More >> Attikon University Hospital Recruiting Athens, Attiki, Greece, 12462 Contact: Paraskevi MATSOTA, MD, PhD    00302105832374    matsota@yahoo.gr    Principal Investigator: PARASKEVI MATSOTA, MD, PHD Less <<
NCT02390284 Glaucoma Phase 3 Recruiting July 2019 United States, Florida ... More >> Bascom Palmer Eye Institute - University of Miami Recruiting Miami, Florida, United States, 33136 Contact: Marlene Perez, RC    305-482-4309    marlene.perez@med.miami.edu    Contact: Shiva Roghaee, RA    305 482 4309    sxr935@med.miami.edu    Principal Investigator: Vittorio Porciatti, DSc          Sub-Investigator: John J McSoley, OD          Sub-Investigator: Luis E Vazquez, MD,PhD          Sub-Investigator: Steven J Gedde, MD          Sub-Investigator: Pedro F Monsalve, RA          Sub-Investigator: Maja Kostic, PhD Less <<
NCT02463357 Mountain Sickness Phase 4 Active, not recruiting November 30, 2018 United States, Michigan ... More >> Alma College Alma, Michigan, United States, 48801 Less <<
NCT00257829 Cervical Cancer Phase 2 Withdrawn(This study was close... More >>d due to lack of funding.) Less << - -
NCT01702025 Physiological Function in Low ... More >>Oxygen Environment Less << Phase 1 Phase 2 Completed - United States, Colorado ... More >> Colorado State University, Dept. of Health and Exercise Science Fort Collins, Colorado, United States, 80523-1582 Less <<
NCT02758470 Hypoxia Phase 4 Completed - Canada, British Columbia ... More >> University of British Columbia Kelowna, British Columbia, Canada, V1V 1V7 Less <<
NCT02760121 Altitude Sickness ... More >> Hypertension, Pulmonary Less << Phase 4 Completed - Canada, British Columbia ... More >> University of British Columbia Kelowna, British Columbia, Canada, V1V 1V7 Less <<
NCT01587027 Mountain Sickness Phase 1 Completed - United States, Colorado ... More >> Medical Center of the Rockies Loveland, Colorado, United States, 80538 Less <<
NCT01702025 - Completed - -
NCT01587027 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.23mL

0.85mL

0.42mL

21.16mL

4.23mL

2.12mL

42.32mL

8.46mL

4.23mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories